A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1c⁺ cells.

ABSTRACT:

Introduction

Immunotherapy is emerging as an efficacious treatment for some cancers, complementing traditional chemo-radiation therapies. Specific markers at the cell surface of cancer cells can be used as immunotherapy targets. However, many of these markers are defined by a patient's genetic background, limiting their use across the human population.

Methods

Here, we investigated the non-polymorphic antigen presenting molecule, CD1c, that is only expressed on subsets of mature hematopoietic cells, as a potential immunotherapy target with reduced risk of off-tumor on-target toxicity in healthy tissues.

Results and discussion

We identified a T cell receptor (TCR) which recognises CD1c in a lipid independent manner and determined the crystal structure of the TCR-CD1c c

SUBMITTER: Szoke-Kovacs R 

PROVIDER: S-EPMC12328196 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature